Stocks and Investing
Stocks and Investing
Mon, June 5, 2017
[ 11:46 AM ] - United States, WOPRAI
[ 11:46 AM ] - United States, WOPRAI
[ 11:46 AM ] - United States, WOPRAI
[ 11:46 AM ] - United States, WOPRAI
[ 11:46 AM ] - United States, WOPRAI
[ 11:46 AM ] - United States, WOPRAI
[ 11:46 AM ] - United States, WOPRAI
[ 11:45 AM ] - United States, WOPRAI
[ 11:45 AM ] - United States, WOPRAI
[ 11:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, June 2, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, June 1, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Amsellem Upgraded (SUPN) to Buy and Increased Target to $44 on, Jun 1st, 2017
David Amsellem of Piper Sandler, Upgraded "Supernus Pharmaceuticals, Inc." (SUPN) to Buy and Increased Target from $30 to $44 on, Jun 1st, 2017.
David, nor any peers, have made any analyst calls on SUPN in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources